Stoke emphasizes that reducing seizures is only part of its goal. The true measure of success for its Dravet syndrome therapy is restoring cognitive and behavioral function, as demonstrated by the Vineland-3 scale. This focus on neurotypical development and quality of life represents a more holistic approach to treating the disease.
The company is well-capitalized with a cash runway extending into 2028, beyond the potential 2027 approval of its Dravet syndrome drug. This strong financial position is bolstered by a strategic co-funding collaboration with Biogen, providing significant stability and de-risking the company's path to commercialization.
The CEO's decision to join Stoke was driven by the familiar, mission-oriented goal of treating a devastating pediatric genetic disease. This mirrors his previous, highly rewarding experience at Vertex, where he helped develop a functional cure for cystic fibrosis, highlighting the power of a compelling personal mission in leadership.
Contrary to investor speculation, the recent departure of a high-profile FDA official has not altered Stoke's regulatory plans. The CEO clarifies they operate under a different FDA center (CEDA) and continue their established path of frequent communication and building a case with Phase 3 data, rather than expecting an accelerated timeline.
Stoke highlights its Open Label Extension (OLE) study as a critical asset. It provides rare longitudinal data, now approaching four years, demonstrating that patients with Dravet syndrome get progressively better "year on top of year." This continuous "gain of function" is a powerful piece of evidence for regulators, clinicians, and investors.
Stoke's therapy for Dravet syndrome employs a unique "upregulation" mechanism. Instead of knocking out a faulty gene or delivering a new one, its ASO targets the existing healthy gene to produce more of the needed NAV1.1 protein. This approach is specifically designed for haploinsufficient diseases where one gene copy is functional but insufficient.